Preoperative prediction of early recurrence in patients with BRAF mutant colorectal cancer using a intergrated nomogram
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Preoperative prediction of early recurrence in patients with BRAF mutant colorectal cancer using a intergrated nomogram ; volume:14 ; number:1 ; day:25 ; month:10 ; year:2024 ; pages:1-13 ; date:12.2024
Scientific reports ; 14, Heft 1 (25.10.2024), 1-13, 12.2024
- Urheber
-
Jin, Zhenbin
Zou, Qin
Zhou, Taohu
Xue, Ting
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-024-77256-2
- URN
-
urn:nbn:de:101:1-2501152116313.923341787038
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:34 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Jin, Zhenbin
- Zou, Qin
- Zhou, Taohu
- Xue, Ting
- SpringerLink (Online service)
Ähnliche Objekte (12)
Optimizing the treatment of BRAF mutant melanoma
Novel combination therapies for BRAF-mutant melanoma
Using a nomogram based on preoperative serum fibrinogen levels to predict recurrence of papillary thyroid carcinoma
Variations of BRAF mutant allele percentage in melanomas
Targeting NG2 relieves the resistance of BRAF-mutant thyroid cancer cells to BRAF inhibitors
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanoma
Inhibition of mitochondrial respiration prevents BRAF-mutant melanoma brain metastasis
Nomogram based on clinical and preoperative CT features for predicting the early recurrence of combined hepatocellular-cholangiocarcinoma: a multicenter study
Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned
Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma
Optimizing the treatment of BRAF mutant melanoma
Novel combination therapies for BRAF-mutant melanoma
Using a nomogram based on preoperative serum fibrinogen levels to predict recurrence of papillary thyroid carcinoma
Variations of BRAF mutant allele percentage in melanomas
Targeting NG2 relieves the resistance of BRAF-mutant thyroid cancer cells to BRAF inhibitors
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanoma
Inhibition of mitochondrial respiration prevents BRAF-mutant melanoma brain metastasis
Nomogram based on clinical and preoperative CT features for predicting the early recurrence of combined hepatocellular-cholangiocarcinoma: a multicenter study
Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned
Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma
Optimizing the treatment of BRAF mutant melanoma
Novel combination therapies for BRAF-mutant melanoma
Using a nomogram based on preoperative serum fibrinogen levels to predict recurrence of papillary thyroid carcinoma
Variations of BRAF mutant allele percentage in melanomas
Targeting NG2 relieves the resistance of BRAF-mutant thyroid cancer cells to BRAF inhibitors
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanoma
Inhibition of mitochondrial respiration prevents BRAF-mutant melanoma brain metastasis
Nomogram based on clinical and preoperative CT features for predicting the early recurrence of combined hepatocellular-cholangiocarcinoma: a multicenter study
Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned